Recombinant Fusion Protein (SiRNAx)

N/A

Report date: 2025/12/12 17:32:25

Base Information

Drug NameRecombinant Fusion Protein (SiRNAx)

Drug Alias NameSingle-Chain Variable Fragment/Modified Human Protamine (SiRNA)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionImmunoglobulin G degraders

TargetsImmunoglobulin G

Therapy Area/IndicationsWaldenstrom Macroglobulinemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniessiRNAx Inc

China Registration ClassN/A

Develop Information

Active CompaniessiRNAx Inc

Inactive CompaniesN/A

Active IndicationsWaldenstrom Macroglobulinemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A